Fierce Pharma

APRIL 5, 2023

AstraZeneca says Lynparza, Imfinzi combo excels in first look at ovarian cancer trial kdunleavy Wed, 04/05/2023 - 10:46

227

227

MedCity News

APRIL 5, 2023

Consumers are demanding the constant need for technology that is simple, connected and convenient, and medtech companies have had to accelerate to meet those needs. They are embracing these changing times and using it as an opportunity to innovate in three key areas.

Medical 110

Medical 110

Fierce Pharma

APRIL 5, 2023

GSK will have to pay additional royalties to AstraZeneca on cancer drug Zejula kdunleavy Wed, 04/05/2023 - 17:03

213

213

MedCity News

APRIL 5, 2023

Avia CEO Linda Finkel has had many conversations with health systems executives about why their technology initiatives haven’t gone as planned in the past. Based on these experiences, she has noticed four main reasons hospitals don’t see the results for which they were hoping — including not exercising enough scrutiny during the vendor selection process and failure to think about capability at scale.

Healthcare 109

Healthcare Healthcare 109

Advertisement

Distribution

Fierce Pharma

APRIL 5, 2023

Bayer's incoming CEO Anderson won't rule out consumer, agriculture spinoffs: report fkansteiner Wed, 04/05/2023 - 10:35

199

199

MedCity News

APRIL 5, 2023

The FDA granted emergency use authorization to an InflaRx antibody drug that treats hospitalized Covid-19 patients. But Pardes Bioscience’s coronavirus journey is ending following the Phase 2 failure of an antiviral that was expected to compete with Pfizer’s Paxlovid.

FDA 101

FDA Patients Biopharma Pharma 101

Pharmaceutical Technology

APRIL 5, 2023

Austrian molecular glue degraders discovery and development company Proxygen and Merck , known as MSD outside the US and Canada, have entered into a multi-year research collaboration and licence deal. Through the collaboration, the companies will work together to identify and develop molecular glue degraders against multiple therapeutic targets. MSD will make an upfront payment to Proxygen, which will also be eligible for up to $2.55bn in future payments, subject to the achievement of agreed res

Engineering 98

Engineering Sales 98

MedCity News

APRIL 5, 2023

To address the burden faced by family caregivers across the country, Tomorrow Health CEO Vijay Kedar argues that the U.S. healthcare system should expand its reimbursement for the care they provide. Not only is caregiving physically and emotionally taxing, but it can also cause severe financial strain —many caregivers take time off work and spend their own money to support their loved ones’ care, he explained.

Healthcare 94

Healthcare Healthcare 94

Pharmaceutical Technology

APRIL 5, 2023

The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) to InflaRx’s Gohibic (vilobelimab) to treat critically ill hospitalised Covid-19 adult patients. Gohibic is indicated for use in these patients within 48 hours of receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO). It is a first-in-class monoclonal anti-human complement factor C5a antibody.

Food and Drug Administration 98

Food and Drug Administration FDA Food Patients 98

MedCity News

APRIL 5, 2023

Preventing drug diversion starts with understanding the signs of a substance use disorder (SUD) in hospital and health system staff workers, those closest to the problem and one of the most affected parties.

Healthcare 90

Healthcare Healthcare Physicians 90

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

Copyright Clearance Center

APRIL 5, 2023

The post CCC Named to KMWorld 100 Companies That Matter in Knowledge Management for 2023 appeared first on Copyright Clearance Center.

Management 98

Management 98

MedCity News

APRIL 5, 2023

With the growing complexity of identity management and the challenges posed by market consolidation and digital front door initiatives, it is essential to implement a solution that will effectively manage patient information and prevent duplicates and identity issues.

Management 87

Management Healthcare Healthcare Marketing 87

European Pharmaceutical Review

APRIL 5, 2023

According to a market report , the global cell and gene therapy (CGT) supply chain/ logistics market is expected to reach $3.12 billion in 2031. This translates into a promising compound annual growth rate (CAGR) of 11.2 percent during the forecast period of 2023-2031. What is driving the cell and gene therapy supply chain/logistics market? The growing need for cell and gene treatments, growing medical trials and improvements in real-time supply chain operations are predicted to enhance the qual

Marketing 77

Marketing Biopharma Manufacturing Government 77

PharmaTimes

APRIL 5, 2023

Individual receives AVA6000 treatment as part of additional dose escalating study

Patients 90

Patients 90

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

Pharmaceutical Technology

APRIL 5, 2023

More than a decade after the first patient was treated with a CAR-T therapy, six therapies relying on the same principles have been approved by the US Food and Drug Administration (FDA) and marketed to thousands of patients. But access to these treatments continues to remain limited due to high price tags and variable availability across regions. Currently, all approved CAR-T therapies are autologous, where T cells taken from patients are modified and then re-infused.

Food and Drug Administration 59

Food and Drug Administration Engineering Patients Education 59

PharmaTimes

APRIL 5, 2023

Company disappointed by institute’s failure to recommend thyroid cancer therapy for specific patient group

Patients 75

Patients 75

Pharmaceutical Technology

APRIL 5, 2023

Caribou Biosciences has secured fast track designation from the US Food and Drug Administration (FDA) for its CAR-T cell therapy, CB-011. The therapy is currently under development for the treatment of patients with relapsed or refractory multiple myeloma (r/r MM). Caribou is presently conducting its Phase l CaMMouflage trial to assess CB-011 in r/r MM patients.

Food and Drug Administration 59

Food and Drug Administration FDA Manufacturing Food 59

Spotio

APRIL 5, 2023

Listen to the episode on Spotify. Chris Pierce is a mental toughness expert who trains sales professionals to double and triple their results. He’s here to help you learn how to do the same. _ Guest At A Glance Name : Chris Pierce What He Does: As a mental toughness expert, Chris has a proven track record of empowering sales professionals to double and even triple their productivity.

Sales 52

Sales Training Leads 52

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

Clarify Health

APRIL 5, 2023

The cost and quality of providers vary widely, even within a single specialty in a single market. Where patients get their medical care directly impacts the cost of care and clinical outcomes. Physicians are often in the driver’s seat when it comes to site of service decisions—they’re making referrals for patients who need to see a specialist or go to a facility.

Physicians 52

Physicians Patients Networking Healthcare 52

PM360

APRIL 5, 2023

The Point of Care Marketing Association (POCMA), a non-profit organization that aims to support the continued growth of the Point of Care (POC) media channel, hosted 270 healthcare marketers at its annual POC NOW Industry Summit at City Winery in New York City , March 22 nd. For the event’s inaugural POC Excellence Awards, POCMA gathered a panel of independent industry experts to review entries across four categories.

Marketing 52

Marketing Education Media Healthcare 52

Quantified

APRIL 5, 2023

In today’s tumultuous job market, finding and retaining top talent is an ongoing priority for most companies. That’s especially true in sales: average turnover among sales reps is almost triple that of other occupations. Tragically, the seeds of disaffection are often planted at the very beginning of a rep’s tenure in the organization.

Sales 52

Sales Sales Management Training Management 52

Pharma Marketing Network

APRIL 5, 2023

Attending the Reuters Pharma Marketing 2023 event on March 28-29 was a fascinating experience as the pharma marketing industry continues to return to in-person events. The event included a focus on Medical Affairs, as a reflection of industry moving away from a ‘church and state’ approach to medical and commercial. We also saw the addition of a track focused on Cell and Gene Therapy, as Pharma ventures into the commercialization of therapeutics.

Pharma 52

Pharma Marketing Competition Networking 52

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization

PharmaVoice

APRIL 5, 2023

Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. Dr. Theresa Heah has spent her entire career moving ophthalm.

52

52

Prognos Health

APRIL 5, 2023

Todd Somsel , Commercial Lead, RWD Marketplace As I reflect on the 2023 edition of the Reuters Pharma conference in Philadelphia last week, I continue to be motivated by the excitement behind the many uses of real-world data (RWD) and the large number of data and service providers growing their offerings in this space. At the same time, the RWD landscape remains tremendously challenging, which threatens to limit the true potential of this rich data source.

Pharma 52

Pharma Leads 52

Pharmaceutical Technology

APRIL 5, 2023

AnaBios has strengthened its human tissue and cells portfolio with the purchase of Cell Systems for an undisclosed sum. Based in Kirkland, Washington, US, Cell Systems is a human primary cell and cell culture media company. The company provides several human primary cells, including endothelial cells from the brain, liver, kidney, eye and lung which facilitate the ongoing evaluation of Covid-19.

Media 52

Media Pharmaceutical Pharma 52

Pharma Leaders

APRIL 5, 2023

UK-based oncology therapeutics company Mosaic Therapeutics has raised $28m from series A funding round. It also announced the appointment of former Novartis Oncology SVP Brian Gladsden as CEO. The firm raised the amount from Syncona Investment Management, and Cambridge Innovation Capital. Proceeds from the Series A funding round will be used to advance Mosaic’s pipeline of targeted oncology therapies for biomarker-stratified populations, advancing its lead programmes via preclinical development

Leads 52

Leads Management 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

Pharmaceutical Technology

APRIL 5, 2023

Luye Pharma Group has signed a marketing and distribution agreement with Duopharma Biotech’s wholly-owned subsidiary, Duopharma Marketing, for a cholesterol management product in Malaysia. Duopharma Marketing will have exclusive rights to market and distribute a traditional Chinese medicine, developed by Luye Pharma for cholesterol management. Duopharma Biotech Group managing director Leonard Ariff Abdul Shatar said: “This partnership and collaboration with Luye Pharma enables all patients in Ma

Management 52

Management Marketing Distribution Pharma 52

Legacy MEDSearch

APRIL 5, 2023

Synapse Biomedical, Inc. announced today that the FDA has granted premarket approval (PMA) of the NeuRx ® Diaphragm Pacing System (NeuRx DPS ® ) for use in patients with spinal cord injuries who rely on mechanical ventilation. PMA is the most stringent type of device marketing application required by FDA. More hospitals are expected to begin implementing the NeuRx DPS ® now that they no longer have to undergo the lengthy internal review and approval process required under the previous humanitari

Patients 52

Patients Recruitment FDA Medical 52

Pharmaceutical Technology

APRIL 5, 2023

The European Medicines Agency (EMA) has announced plans to expedite scientific advice and support the preparation of regulatory packages under its PRIority Medicines (PRIME) scheme. PRIME is an EMA scheme to support the development of medicines for rare diseases and conditions with high unmet need. Last year, the EMA approved 49 new medicines , of which eight were recommended for approval through the PRIME scheme.

Medicine 52

Medicine Marketing 52

PharmExec

APRIL 5, 2023

Kevin Hagan, president and CEO of the PAN Foundation, spoke to PharmExec about the recent IRA changes to Medicare and how it positively effects patients.

Patients 52

Patients Pharma 52

Advertisement

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

Management